Standard-Dose influenza virus surface antigens (haemagglutinin and neuraminidase), Inactivated, Influenza Vaccine Quadrivalent, 2019-2020 Northern Hemisphere Strains (QIV-SD)

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Influenza Immunization

Drug Information

Target Indication

Influenza Immunization

Clinical Trial

Last updated: 12/27/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

SNY

Sanofi

Related Pipeline

Sleep Initiation and Maintenance Disorders

Hemophilia A

Ulcerative Colitis

Alzheimer Disease

Influenza

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts